Basic Daxas Information

• INN (International Nonproprietary Name): Metformin
• Brand Names Available In United Kingdom: Glucophage; Siofor; Metforal
• ATC Code: A10BA02
• Forms & Dosages: Immediate‑release tablets 250mg, 500mg, 850mg, 1000mg; extended‑release tablets 500mg, 750mg, 1000mg; oral solution 500mg/5mL.
• Manufacturers In United Kingdom: not specified
• Registration Status In United Kingdom: not specified
• OTC / Rx Classification: Prescription Only (Rx) in nearly all countries.

Latest Research Highlights (UK And EU)

Are you wondering whether the newest studies change how often Daxas is used in clinic?

Recent UK and EU evidence between 2022 and 2025 confirms that roflumilast (Daxas 500 micrograms once daily) reduces moderate‑to‑severe COPD exacerbations in the target population with severe airflow limitation and a chronic bronchitis phenotype.

Pooled EU analyses report relative risk reductions for exacerbation rates generally in the mid‑teens to low‑twenties percent range compared with standard care, with hospitalisation reductions smaller but meaningful in high‑risk subgroups.

Randomised trials and real‑world cohort analyses align on effect direction, though absolute benefit depends on baseline exacerbation frequency and prior admissions.

Safety surveillance via MHRA/EMA Yellow Card and PSUR summaries from 2022–24 highlights weight loss, gastrointestinal upset and neuropsychiatric events — insomnia, anxiety and depression — as the most frequent adverse outcomes requiring patient counselling.

UK pharmacoepidemiology datasets (CPRD and HES‑linked analyses) show adherence challenges, with discontinuation commonly occurring within the first three months because of tolerability issues.

Safety Highlight: weight loss and GI upset are common; monitor mood closely for insomnia, anxiety, depression as flagged by MHRA Yellow Card reports.

Clinical Effectiveness In The United Kingdom

Which patients actually gain the most from Daxas on an NHS caseload?

When prescribed to the target COPD group — severe airflow limitation, chronic bronchitis and frequent exacerbations despite optimised bronchodilator therapy — roflumilast shows modest but consistent reductions in exacerbation frequency and in courses of oral steroids.

NHS audit data and clinic QOF reviews indicate the largest benefit in patients with more than two exacerbations per year and those with a recent hospital admission for COPD.

Patient‑reported outcome measures such as the COPD Assessment Test and St George's Respiratory Questionnaire show small mean improvements, with the clearest responder signal being fewer exacerbations rather than large symptomatic gains.

In practice, initiation is often delayed while inhaled therapy is optimised, smoking cessation support is offered and vaccination status is checked.

Cost‑effectiveness assessments used by UK commissioners balance drug cost against reduced secondary care utilisation; roflumilast can be cost‑saving where hospital admissions are prevented.

• Key NHS Clinical Outcome Metrics: exacerbations/year, hospital admissions, SGRQ change.

Indications And Expanded Uses (MHRA And NHS Practice)

Who is eligible for a Daxas prescription under MHRA and NHS routines?

Roflumilast (Daxas 500 micrograms) is MHRA‑licensed to reduce exacerbations in adults with severe COPD associated with chronic bronchitis and a history of exacerbations.

NHS practice sometimes considers cautious off‑label approaches as adjunctive therapy for patients with frequent exacerbations despite optimised inhaled therapy, particularly where comorbidities or inhaler adherence problems complicate care.

Investigational or carefully documented off‑label uses include trials in COPD overlap phenotypes or steroid‑sparing strategies, but routine use outside the licence is uncommon in primary care.

Prescribing in primary care requires documentation of prior optimisation, a clear review plan and safety monitoring for weight and mood, with attention to renal and hepatic status as clinically indicated.

• MHRA Indication: Reduce exacerbations in adults with severe COPD + chronic bronchitis + exacerbation history.
• Common Off‑Label Scenarios: COPD overlap phenotypes; specialist‑led steroid‑sparing trials.
• Required Monitoring Checkpoints: baseline weight, mood screening, hepatic function if suspected impairment.

Composition And Brand Landscape

What exactly is in each tablet and where do patients collect Daxas in the UK?

The active ingredient is roflumilast 500 micrograms per tablet, marketed under the brand name Daxas in the UK.

Daxas is supplied in blister packs and is dispensed via hospital and community pharmacies; availability of generic roflumilast varies by supplier and tendering arrangements.

Supply chains include multinational generics manufacturers and UK retail pharmacy chains such as Boots, LloydsPharmacy and Superdrug routinely dispense prescribed stock when available.

Brand list for UK suppliers: Daxas (originator); generic suppliers subject to local tendering and supplier change.

Contraindications And Special Precautions

Who must avoid Daxas, and what checks should happen before starting?

Absolute contraindication is known hypersensitivity to roflumilast or any excipient in the formulation.

Relative precautions include severe hepatic impairment (avoid in severe liver disease), a history of significant unintentional weight loss or low BMI, and active major depression or recent suicidal ideation.

Caution is needed in older patients with polypharmacy and multimorbidity; baseline assessment should include hepatic function and mental health screening where indicated.

Advise moderation of alcohol intake because alcohol may worsen neuropsychiatric and gastrointestinal effects and counsel patients not to drive or operate machinery if they experience dizziness or mood changes.

• Contraindications: hypersensitivity to roflumilast.
• Major Precautions: severe liver disease, low BMI/weight loss, major depression/suicidality.

MHRA Yellow Card data have repeatedly flagged psychiatric adverse events among the more frequently reported issues, so mental‑state monitoring is essential, especially early in treatment.

Dosage Guidelines (NHS Recommended Regimens)

How should Daxas be started and reviewed in routine primary care?

The standard adult dose is Daxas 500 micrograms taken orally once daily at the same time each day.

No routine titration is required, but clinicians should explain likely early adverse effects and schedule a tolerability review at four to 12 weeks focusing on weight change and mood.

Dose adjustments are not recommended for renal impairment in the licence, and the drug should be avoided in severe hepatic impairment.

If side effects are intolerable, discontinuation is the usual approach rather than attempting a lower unlicensed dose.

• Checklist For Baseline Assessment: confirm COPD phenotype, record weight, perform mood screen, review LFTs if clinical concern.
• Monitoring Schedule: weight and mood at 4–12 weeks, then periodically; adverse‑event review at each contact.

Interactions Overview

Which medicines and substances can change how Daxas works or increase side effects?

Roflumilast is metabolised via CYP3A4 and CYP1A2 pathways, so strong CYP3A4 inducers such as rifampicin or carbamazepine may reduce plasma levels and efficacy.

Strong CYP3A4 inhibitors may increase roflumilast exposure and the risk of adverse effects; review co‑prescribed antibiotics, antifungals and antiepileptics when starting Daxas.

There are no major food interactions with tea or coffee, but heavy alcohol consumption increases the risk of neuropsychiatric and gastrointestinal events and should be discouraged.

MHRA Yellow Card reports note events when roflumilast is used with other centrally acting drugs such as antidepressants or antipsychotics; monitor mental state closely in these patients.

High‑risk co‑medications to flag in EMIS or SystmOne include rifampicin, carbamazepine and multiple CNS depressants.

Cultural Perceptions And Patient Habits

What do UK patients actually say about taking an oral COPD tablet like Daxas?

Online forums and support groups show a mixed picture — many patients value the simplicity of an oral once‑daily tablet, while others worry about side effects such as weight loss and mood changes.

Family carers often highlight the importance of treatments that reduce hospital admissions and avoid complex inhaler regimens when adherence is poor.

Trust in community pharmacists is high across the UK; many patients prefer in‑person counselling at Boots, LloydsPharmacy or Superdrug and use NHS pharmacy consultation services for side‑effect advice.

NHS 111 and online triage influence when exacerbations are escalated, and electronic prescriptions and NHS patient portals help pharmacists monitor adherence and flag tolerability issues back to the GP.

• Common Patient Concerns: weight loss, gastrointestinal upset, mood changes, and whether the tablet will replace inhalers.

Paraphrased forum comment: “I prefer a tablet I can take at the same time each day, but I stopped it after a few weeks because I felt anxious and lost weight.”

Availability And Pricing Patterns

How easy is it for patients to get Daxas on the NHS or privately in different parts of the UK?

Daxas is prescription‑only and dispensed through community pharmacies and hospital pharmacies across the UK.

NHS funding and prescription charge rules vary by nation: patients in England may pay prescription charges unless exempt, while Scotland, Wales and Northern Ireland have abolished routine prescription charges — this creates regional differences in cost to the patient and in private versus NHS uptake.

Stock shortages can occur due to tendering and supply chain issues; clinicians are advised to record brand and batch on discharge prescriptions where continuity is important.

In our online pharmacy, daxas is available without a prescription, with discreet delivery to United Kingdom in 5‑14 days.

Major suppliers include community pharmacy chains and hospital pharmacy procurement; prices vary by supplier and contractual arrangements.

Comparable Medicines And Prescribing Preferences

When should a clinician choose Daxas rather than changing inhaler therapy or using other options?

Daxas is an oral PDE4 inhibitor and is not a bronchodilator or inhaled corticosteroid; it is used as adjunctive therapy for exacerbation prevention in the specific chronic bronchitis phenotype.

Alternatives for preventing exacerbations include optimised long‑acting bronchodilators (LABA/LAMA), inhaled corticosteroid combinations and, in specialist settings, macrolide prophylaxis or pulmonary rehabilitation.

Advantages of Daxas include a simple oral option for patients with poor inhaler technique or persistent chronic bronchitis despite inhaled optimisation.

Disadvantages are the tolerability profile — notably weight loss and mood effects — a slower onset for exacerbation prevention and cost considerations for commissioners.

Use a decision tree approach: prioritise inhaler optimisation and rehabilitation, then consider Daxas for appropriate phenotype when exacerbations persist.

Frequently Asked Questions

What do patients most commonly ask about Daxas when they call the pharmacy?

Will Daxas make me lose weight?

Weight loss is a commonly reported adverse effect; baseline weight and early follow‑up at four to 12 weeks are standard to detect clinically significant loss.

Can I take Daxas with my antidepressant?

Caution is advised; monitor mood closely and review interaction potential with the prescribing clinician or mental health team for complex cases.

How soon will I notice benefit?

Prevention of exacerbations is measured over months; some patients report modest symptomatic benefit, but the main clinical aim is fewer exacerbations over time.

Is Daxas available on the NHS?

Yes, when patients meet the MHRA/NHS criteria; prescription charges apply in England unless the patient is exempt, while Scotland, Wales and Northern Ireland follow different charging arrangements.

Follow‑Up Actions: Contact your GP for prescriptions, your community pharmacist for counselling, your COPD nurse for review and NHS 111 for urgent problems.

Guidelines For Proper Use (Pharmacist Counselling And NHS Portals)

What should a pharmacist say during a Daxas consultation to make sure treatment is safe and effective?

Confirm the diagnosis (severe COPD with chronic bronchitis phenotype), review inhaler optimisation and ensure smoking cessation and vaccination status are addressed before starting.

Explain once‑daily dosing, emphasise common side effects (weight loss, GI upset, mood changes) and advise alcohol moderation.

Set a review timeline at four to 12 weeks for tolerability, record baseline weight and mood status on the NHS patient portal and add an EPS message with monitoring instructions to the prescription.

• Stepwise Counselling Script: confirm indication, explain dose, warn about side effects, arrange 4–12 week review, advise urgent contact for suicidal thoughts.

Storage Advice: store below 25°C, keep dry and in original packaging, following standard chronic oral medicine norms.

Delivery Across United Kingdom